文献速递神经肿瘤

DNA损伤应答谱可区分共享甲基化特征的预后不良胶质瘤

DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures.
PubMed 文献 · Neuro Oncol · 2026-01-01

本研究分析TCGA胶质母细胞瘤与低级别胶质瘤的DNA损伤应答(DDR)表观遗传与基因表达,并对118例弥漫性胶质瘤行单细胞蛋白成像质谱分析。DDR甲基化分组与IDH突变状态相关,DDR转录分组可区分生存,高DDR转录与不良生存独立相关。

要点

  • DDR甲基化与转录特征可在现有生物标志物之外辅助胶质瘤分子诊断与预后判断。
  • 跨通路DDR高转录与较差生存相关,且独立于IDH或MGMT状态。
  • 跨通路DDR效应蛋白高表达的增殖性肿瘤细胞增多与不良分级和生存相关。

核心结论

  • 肿瘤层面的表观遗传与转录DDR特征可区分胶质瘤的分子诊断与结局,并超越现有生物标志物。
  • 跨通路DDR效应蛋白高表达的胶质瘤细胞丰度较高与不良生存相关。
  • 临床评估泛DDR表达可能有助于预后判断并识别潜在治疗靶点。

研究设计与样本

  • 基于TCGA胶质母细胞瘤(GBM)与低级别胶质瘤(LGG)队列分析DDR表观遗传与基因表达。
  • 对另一独立队列的118例弥漫性胶质瘤行成像质谱(IMC)单细胞蛋白分析。

主要发现

  • TCGA队列分析发现两个DDR甲基化分组,与IDH突变状态及既往报道的分子分组相关。
  • DDR转录谱进一步将肿瘤分为四组。
  • 跨通路DDR高转录与较差生存相关,且独立于IDH或MGMT状态,并可能改善现有生物标志物之外的预后判断。
  • 单细胞分析显示瘤内DDR多样性,并识别出跨通路DDR蛋白高表达的增殖性肿瘤细胞,与不良分级和生存相关。

临床怎么用

  • 可考虑将肿瘤层面DDR表观遗传与转录特征用于辅助胶质瘤分子诊断与预后分层。
  • 评估跨通路DDR表达及DDR高表达肿瘤细胞丰度可能帮助识别预后不良患者与潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapies for diffuse glioma induce DNA damage response (DDR), and strategies to exploit DDR defects are active areas of investigation. While global DNA methylation profiling effectively classifies gliomas into subtypes, the epigenetic and gene expression patterns of DDR genes, and their contribution to tumor classification and outcomes, have yet to be fully elucidated. Thus, dissecting the DDR epigenetics, gene expression, and single-cell heterogeneity may reveal key molecular characteristics, refine prognosis, and identify novel treatment strategies and resistance mechanisms. METHODS: We characterized DDR epigenetics and gene expression of TCGA glioblastomas (GBM) and low-grade gliomas (LGG). Single-cell protein analysis by imaging mass cytometry (IMC) was performed on a separate cohort of 118 diffuse gliomas. RESULTS: Analysis of TCGA cohorts revealed two DDR methylation groups that correlated with IDH mutation status and previously reported molecular groups. DDR transcription profiling further classified tumors into four groups. Those with high DDR transcription across pathways were linked to poor survival independent of IDH or MGMT status, and potentially improved prognostication beyond established biomarkers. Single-cell characterization of a separate cohort revealed intratumoral DDR diversity and identified proliferative tumor cells with high DDR protein expression across pathways that are associated with unfavorable grade and survival. CONCLUSIONS: Tumor-level epigenetic and transcriptional DDR signatures alone can distinguish molecular-defined diagnosis and outcomes of gliomas beyond established biomarkers. A higher abundance of glioma cells with high DDR effector expression across pathways is associated with poor survival. Thus, clinical assessment of pan-DDR expression may inform prognosis and identify potential therapeutic targets.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Leelatian N, Singh C, Bouffard R, et al. DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures. Neuro Oncol. 2026. PMID: 40887772. doi:10.1093/neuonc/noaf199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。